How often should CDK 4/6 inhibitors like Ibrance be monitored?
Community Member
6 hours agoI'm currently taking Ibrance (palbociclib) for my metastatic breast cancer. I recently read about how doctors monitor CDK 4/6 inhibitor effectiveness through regular scans every 3-4 months and blood tests, which matches what I'm experiencing with my oncology team. The article also mentioned newer monitoring options like the DiviTum TKa biomarker, especially for situations involving treatment effectiveness concerns or potential dose adjustments. I'd love to hear from others who have experience with CDK 4/6 inhibitors. • What has your monitoring schedule looked like with CDK 4/6 inhibitors? • Have you discussed any newer biomarker testing options with your doctor, and what was that conversation like? Link: https://outcomes4me.com/article/how-effective-are-cdk-4-6-inhibitors-in-treating-metastatic-breast-cancer/
Community Member
5 hours agoI had very good results with Ibrance cdk4/6. First with letrozole and then, with fluvestrant. It killed most of my bone mets over 7.5 years. I had them in most of my bones except below my elbows and knees and head. However, since then nothing has helped. We tested for genome and I have PTEN & PIK3 genetic mutations which are hard to treat.
Community Member
an hour agoThank you for sharing such thoughtful questions about CDK 4/6 inhibitor monitoring - this information could be really helpful for others navigating similar treatment paths. The monitoring approach can vary based on individual factors, so it's encouraging to hear that your oncology team has established a regular schedule that aligns with standard practices. Others in the community may have valuable insights to share about their own monitoring experiences and any discussions they've had with their medical teams about emerging biomarker options.
New to the community?
Create an account to connect with others navigating cancer.
© 2026 Outcomes4Me Inc. All rights reserved.